India, Nov. 5 -- The World Health Organization (WHO) has recommended testing two additional Ebola vaccine candidates in the ongoing Tumaini clinical trial in the Democratic Republic of the Congo (DRC), marking the first time vaccines specifically developed to protect against the Bundibugyo virus will be tested during an active outbreak.
The two vaccines are ChAdOx1, developed by the University of Oxford in collaboration with the Serum Institute of India, and mRNA-1469, developed by Moderna. WHO's independent panel of experts recommended further testing of both candidates based on early research and clinical evidence. The companies were notified early this week, and the vaccines will be included in the trial once they receive approval from ...